Mf. Goldstein et al., Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease, CHEST, 116(6), 1999, pp. 1733-1749
Citations number
125
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Long-term glucocorticoid (GC) therapy has been instrumental in decreasing m
orbidity and mortality in a variety of chronic inflammatory diseases, inclu
ding persistent asthma, Long-term GC therapy is also widely prescribed for
COPD, One of the important and often unrecognized side effects of chronic G
C therapy is secondary osteoporosis, The risk of GC-induced bone loss is ro
ughly correlated with daily desk, duration, and total cumulative lifetime d
ose of GC treatment. Oral prednisone increases the risk of bone loss and fr
acture. High doses of inhaled GCs may also increase the risk of osteopenia/
osteoporosis, but the risk appears to be less than that associated with ora
l GCs, Hormone replacement therapy, oral and parenteral bisphosphonates, su
pplemental calcium and vitamin D, calcitonin, and fluoride compounds have b
een used, experimentally, in the management of GC-induced bone loss. Asthma
and GOLD specialists are key prescribers of oral and inhaled steroids and
are likely to encounter patients with significant bone loss. Despite known
risk factors and the availability of reliable diagnostic tools to recognize
bone loss, the opportunity to slow, reverse, and treat bone loss is often
missed, We present a review of the current literature regarding the inciden
ce, treatment, and prevention of osteopenia/osteoporosis secondary to chron
ic GC therapy in adult asthma and COPD patients. Guidelines are presented r
egarding the identification of patients at risk for developing GC-induced s
econdary bone loss, and therapeutic alternatives are discussed.